News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Alcon, Inc. (ACL) Independent Director Committee Notes RiskMetrics's and Glass Lewis' Opposition to Election of Novartis Corporation (NVS)’ Designees to Alcon’s Board of Directors



8/2/2010 7:37:26 AM

HUENENBERG, Switzerland--(BUSINESS WIRE)--The Alcon Independent Director Committee (the “IDC”) today announced that RiskMetrics Group, Inc. and Glass Lewis & Co., two global leaders in risk management, corporate governance and proxy advisory services, have both recommended that Alcon minority shareholders vote against all five of Novartis AG’s (“Novartis”) designees to the Alcon board of directors. As previously announced, pursuant to the terms of agreements between Novartis and Nestlé SA entered into in 2008, Alcon shareholders will vote on the conditional election of Novartis’ board designees at an extraordinary general meeting on August 16, 2010.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES